These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 22999165)

  • 1. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Ishani A; Rector T; Fitzgerald P; MacDonald R; Tacklind J; Rutks I; Wilt TJ
    Am J Kidney Dis; 2012 Nov; 60(5):747-69. PubMed ID: 22999165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of dialysis initiation, duration and frequency of hemodialysis sessions, and membrane flux: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Greer N; Ishani A; MacDonald R; Olson C; Rutks I; Wilt TJ
    Am J Kidney Dis; 2015 Nov; 66(5):823-36. PubMed ID: 26498415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
    Sarnak MJ; Bloom R; Muntner P; Rahman M; Saland JM; Wilson PW; Fried L
    Am J Kidney Dis; 2015 Mar; 65(3):354-66. PubMed ID: 25465166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline.
    Fink HA; Ishani A; Taylor BC; Greer NL; MacDonald R; Rossini D; Sadiq S; Lankireddy S; Kane RL; Wilt TJ
    Ann Intern Med; 2012 Apr; 156(8):570-81. PubMed ID: 22508734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
    de Boer IH; Gao X; Cleary PA; Bebu I; Lachin JM; Molitch ME; Orchard T; Paterson AD; Perkins BA; Steffes MW; Zinman B;
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1969-1977. PubMed ID: 27797889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD.
    Nelson RG; Tuttle KR
    Blood Purif; 2007; 25(1):112-4. PubMed ID: 17170547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort.
    Hellemons ME; Denig P; de Zeeuw D; Voorham J; Lambers Heerspink HJ
    Nephrol Dial Transplant; 2013 Mar; 28(3):706-15. PubMed ID: 23262433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study.
    Abdel-Kader K; Greer RC; Boulware LE; Unruh ML
    BMC Nephrol; 2014 Apr; 15():64. PubMed ID: 24755164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials.
    Usman M; Gillies CL; Khunti K; Davies MJ
    Diabetes Res Clin Pract; 2018 Dec; 146():76-84. PubMed ID: 30312714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes.
    Targher G; Mantovani A; Pichiri I; Mingolla L; Cavalieri V; Mantovani W; Pancheri S; Trombetta M; Zoppini G; Chonchol M; Byrne CD; Bonora E
    Diabetes Care; 2014 Jun; 37(6):1729-36. PubMed ID: 24696459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.
    Upadhyay A; Earley A; Lamont JL; Haynes S; Wanner C; Balk EM
    Ann Intern Med; 2012 Aug; 157(4):251-62. PubMed ID: 22910936
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.